Low Dose Ruxolitinib in Indian Haplo-Identical Transplant Patients with Steroid Refractory Acute Graft Versus Host Disease

被引：0
|
作者：
Kumar, Kishore [1 ]
Prabhu, Durai [2 ]
Kandan, Mani [3 ]
Thooran, Sen [3 ]
Subash, Chezhian [1 ]
机构：
[1] MIOT Inst Haematol, Chennai, Tamil Nadu, India
[2] MIOT Int Hosp, Chennai, Tamil Nadu, India
[3] MIOT, Chennai, Tamil Nadu, India
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157269
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12893 / 12894
页数：2
相关论文
共 50 条
  • [31] Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
    Mahmoudjafari, Zahra
    Bhatt, Valkal
    Galvin, John
    Xue, Zhenyi
    Zeiser, Robert
    Locatelli, Franco
    Socie, Gerard
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2025, 60 (01) : 69 - 78
  • [32] Ruxolitinib plus etanercept for patients with steroid-refractory acute graft versus host disease after allogeneic stem cell transplantation
    Zhao, Yanmin
    Shi, Jinmin
    Luo, Yi
    Tan, Yamin
    Lan, Jianping
    Chen, Lieguang
    Huang, He
    BONE MARROW TRANSPLANTATION, 2019, 54 : 298 - 298
  • [33] Low dose alemtuzumab is effective in the treatment of severe steroid-refractory acute graft-versus-host disease
    Repp, R
    Claviez, A
    Gahn, B
    Schub, N
    Beck, C
    Helm, F
    Gramatzki, M
    BONE MARROW TRANSPLANTATION, 2006, 37 : S97 - S97
  • [34] Sequential haplo-identical conditioning transplant regimen for pediatric patients with relapsed or refractory hemophagocytic lymphohistiocytosis
    Yan Yue
    Shifen Fan
    Zhouyang Liu
    Fan Jiang
    Jiao Chen
    Jiayue Qin
    Yuan Sun
    Bone Marrow Transplantation, 2024, 59 : 513 - 517
  • [35] A single centre experience of ruxolitinib for treatment of steroid refractory chronic graft versus host disease
    Kirkham, Z.
    Ethell, M.
    Potter, M.
    Arias, C. Gonzalez
    Davis, K.
    Dallas, F.
    Salmen, C.
    Anthias, C.
    Nicholson, E.
    Easdale, S.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 215 - 215
  • [36] Tocilizumab for steroid refractory acute graft-versus-host disease
    Roddy, Julianna V. F.
    Haverkos, Bradley M.
    McBride, Ali
    Leininger, Kathryn M.
    Jaglowski, Samantha
    Penza, Sam
    Klisovic, Rebecca
    Blum, William
    Vasu, Sumithira
    Hofmeister, Craig C.
    Benson, Don M.
    Andritsos, Leslie A.
    Devine, Steven M.
    Efebera, Yvonne A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 81 - 85
  • [37] Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience
    Xue, Elisabetta
    Lorentino, Francesca
    Pavesi, Francesca
    Assanelli, Andrea
    Peccatori, Jacopo
    Bernardi, Massimo
    Corti, Consuelo
    Ciceri, Fabio
    Stanghellini, Maria Teresa Lupo
    LEUKEMIA RESEARCH, 2021, 109
  • [38] Pentostatin in steroid refractory acute graft versus host disease.
    Jacobsohn, D
    Margolis, J
    Anders, V
    Phelps, M
    Grever, M
    Vogelsang, G
    BLOOD, 2002, 100 (11) : 420A - 420A
  • [39] BORTEZOMIB FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (GVHD)
    Wagner, J. L.
    Mookajee, B.
    Filicko-O'Hara, J. E.
    Grosso, D. A.
    Flomenberg, N.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S370 - S370
  • [40] ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease
    Hamad, Nada
    Bilmon, Ian
    Chee, Lynette
    Henden, Andrea
    Johnston, Anna
    Purtill, Duncan
    Bajel, Ashish
    Tey, Siok-Keen
    Yeung, David
    Cole, Theresa
    Lewis, Clinton
    Butler, Jason
    INTERNAL MEDICINE JOURNAL, 2023, 53 (12) : 2319 - 2329
12345